June 2013 Br J Cardiol 2013;20:65 doi:10.5837/bjc.2013.17 Online First
Magdalena Polanska-Skrzypczyk, Maciej Karcz, Pawel Bekta, Cezary Kepka, Jakub Przyluski, Mariusz Kruk, Ewa Ksiezycka, Andrzej Ciszewski, Witold Ruzyllo, Adam Witkowski
Introduction Myocardial infarction with persistent ST-elevation (STEMI) continues to be a major public health problem. In a recent report, the incidence of hospital admissions for STEMI in Europe varied between 44 and 142 per 100,000 inhabitants per year, and in-hospital mortality reached 13.5%.1 More than 30% of STEMI patients have chronic kidney disease (CKD).2 On the other hand, half of deaths in advanced CKD patients are of cardiovascular causes with myocardial infarction (MI) being the most frequent event.3 Patients with CKD are routinely excluded from cardiovascular clinical trials, and certain medications and treatment modalities are l
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits